Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw
- 21 May 2013
- journal article
- Published by Wiley in Transfusion
- Vol. 54 (2), 418-425
- https://doi.org/10.1111/trf.12254
Abstract
Cryosupernatant plasma (CSP) is used in Canada for plasma exchange in thrombotic thrombocytopenic purpura. The refrigerated storage time for thawed CSP is limited in many areas to not more than 24 hours postthaw. Because large volumes of CSP are needed for plasma exchange, procedural postponement can lead to product wastage. To determine if CSP storage could be extended, we measured coagulation-related activities in CSP thawed and stored at 1 to 6°C for up to 5 days. Thirty-six CSP units were thawed, refrigerated, and sampled aseptically at 0, 24, 48, and 120 hours postthaw. Clotting factor activities (Factor [F]V, FVII, FVIII, and fibrinogen) and prothrombin time were measured using an automated coagulation analyzer, and von Willebrand factor (vWF) and ADAMTS13 activities using enzyme-linked immunosorbent assay. Fibrinogen, FVIII, and vWF activities were unchanged from thaw values after 120 hours of storage; ADAMTS13, FV, and FVII activities were significantly lower than at thaw, but mean reductions were only -2.6, -7.7, and -12%, respectively. Losses were proportionately greater in the first 24 hours of refrigerated storage. Extending the refrigerated storage of CSP from 1 to 5 days had little impact on product quality. The retention of more than 97% of initial mean ADAMTS13 activity after 5 days of refrigerated storage suggests that the shelf life of thawed refrigerated CSP could be extended without meaningful losses of its likely most important ingredients. CSP postthaw storage could be aligned to that of refrigerated thawed frozen plasma, currently available for transfusion in some jurisdictions for up to 5 days postthaw.This publication has 35 references indexed in Scilit:
- Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic–uraemic syndrome: an analysis of the German STEC-HUS registryNephrology Dialysis Transplantation, 2012
- Thrombotic MicroangiopathiesISRN Hematology, 2012
- Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathwaysBlood, 2011
- Reversal of vitamin K antagonists prior to urgent surgeryCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2010
- Pathophysiology of thrombotic thrombocytopenic purpuraInternational Journal of Hematology, 2010
- Cryoprecipitate: The Current State of KnowledgeTransfusion Medicine Reviews, 2009
- Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpuraNature, 2001
- Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic PurpuraThe New England Journal of Medicine, 1998
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 1998
- High-potency Antihæmophilic Factor Concentrate prepared from Cryoglobulin PrecipitateNature, 1964